Trial Profile
A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 03 Apr 2013 Primary endpoint 'Pain-intensity' has been met.
- 03 Apr 2013 Results published in JAMA: the Journal of the American Medical Association.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed.